# Candel Therapeutics (CADL) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/CADL
## Company Profile
- Ticker: CADL
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunotherapy, Oncology
## Stock Data
- Close: 10.23 USD
- Market cap: 616935412.38 USD
- Last updated: 2026-10-05
## Business Overview
### Multimodal Cancer Immunotherapy
Candel Therapeutics develops locally administered viral immunotherapies intended to induce immunogenic tumor-cell death and a systemic antitumor immune response.
### Aglatimagene Besadenovec
Aglatimagene is an off-the-shelf, replication-defective adenovirus that delivers the HSV-thymidine-kinase gene into tumors. It is paired with valacyclovir to trigger local cytotoxicity and immune activation.
### Prostate Cancer Program
A pivotal Phase 3 study demonstrated improved disease-free survival when aglatimagene was added to radiotherapy in localized intermediate- to high-risk prostate cancer. The company is preparing a BLA based on this program.
### Lung Cancer Expansion
The global Phase 3 AURORA study evaluates aglatimagene in advanced non-squamous non-small-cell lung cancer progressing after pembrolizumab.
### Linoserpaturev
Linoserpaturev is a replication-competent oncolytic herpes-simplex-virus therapy in development for recurrent glioblastoma and other solid tumors.
## Why The Stock Is Moving

As of Oct 5, 2026, CADL closed up 0.49% at $10.23. No new same-company headline was identified in the current news window.

## Future Catalysts

- Submission of a BLA for aglatimagene in localized prostate cancer in the fourth quarter of 2026.
- Potential U.S. commercial launch of aglatimagene in 2027, subject to approval.

## Drug Assets

- CAN-2409

## Recent News
- 2026-10-02 13:00 EST — [Candel Therapeutics to Present at the SITC 2026 Annual Meeting](https://biopharmsignal.com/news/CADL/candel-therapeutics-to-present-at-the-sitc-2026-annual-meeting-5a750832) — Source: Candel Therapeutics
- 2026-10-01 20:05 EST — [Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/CADL/candel-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-7240e65f) — Source: Candel Therapeutics
- 2026-10-01 12:05 EST — [Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI](https://biopharmsignal.com/news/CADL/candel-therapeutics-announces-publication-of-phase-2a-trial-data-that-demonstrat-7cf683a1) — Source: Candel Therapeutics
- 2026-09-30 12:30 EST — [Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer](https://biopharmsignal.com/news/CADL/candel-therapeutics-announces-integrated-clinical-and-biomarker-data-that-showed-efa3ccdb) — Source: Candel Therapeutics
- 2026-09-30 12:05 EST — [Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026](https://biopharmsignal.com/news/CADL/candel-therapeutics-announces-new-data-showing-sustained-immune-remodeling-more--3cd173a7) — Source: Candel Therapeutics